IQVIA Holdings (IQV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

IQVIA Holdings

NYSE•Healthcare•Diagnostics & Research

$269.44+0.62(<0.01%)After hours

Market Cap

$44.75B

P/E

32.5x

P/S

2.6x

P/B

7.3x

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

How this company scores

GoodMetricSide Score: 69/100

Strongest: Cash & Earnings Quality (23/25); weakest: Balance Sheet & Red Flags (8/25).

Profitability19/25

Growth19/25

Balance Sheet & Red Flags8/25

Cash & Earnings Quality23/25

Strengths

High ROECash-backed earningsConsistent free cash flowConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 32.5x5y range 20.2x – 60.6x

Currently near its 20-quarter median.

P/S · 2.6x5y range 1.7x – 3.9x

Currently near its 20-quarter median.

P/B · 7.3x5y range 4.5x – 8.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 6.6% — watch for continued compression, which may signal competitive or cost pressure.

Leverage Risk

Watch

D/E ratio of 2.2 is elevated. Watch for further debt accumulation.

Price & Volume

Market Cap $44.75B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $16.98B
Q. Revenue: $4.37B
TTM EBITDA: $3.38B
TTM Op. Income: $2.20B
Q. Op. Income: $506.00M
TTM Net Income: $1.38B
Q. Net Income: $256.00M
EPS: $1.54
Shares Out.: $166.10M

$16.98B in TTM revenue grew 8.2% YoY, reaching $4.37B last quarter. TTM EBITDA of $3.38B and TTM operating income of $2.20B show growth is flowing through to the bottom line. TTM net income of $1.38B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 18.3%
Op. Margin: 11.6%
Net Margin: 5.9%

Op. margin of 11.6% is down 1.0% YoY — costs are rising relative to revenue. Net margin at 5.9% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 32.5x
P/S Ratio: 2.6x
P/B Ratio: 7.3x

At 32.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 2.6x and P/B of 7.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 49% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $29.88B
Cash: $1.91B
Long-Term Debt: $13.71B
Book Value: $6.17B
D/E Ratio: 2.2
Debt/EBITDA: 17.2

With $29.88B in assets and $13.71B in long-term debt, D/E is 2.2and book value is $6.17B — elevated leverage, meaning significant financial risk in a downturn. Over the past year, debt/equity is down 9% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $558.00M
TTM Free Cash Flow: $2.18B
FCF Margin: 12.9%
FCF / Net Income: 1.6

TTM FCF of $2.18B on $558.00M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.